Cytokinetics (CYTK) Tops Q3 EPS by 7c

Cytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($0.23), $0.07 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $7.9 million versus the consensus estimate of $11.24 million.

For earnings history and earnings-related data on Cytokinetics (CYTK) click here.

You May Also Be Interested In

• Stran & Company, Inc. (SWAG) Reports Q2 EPS of $0.02
• Transact Technologies (TACT) Tops Q2 EPS by 1c
• Snail, Inc. (SNAL) Reports Q3 Loss of $0.36